These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9523162)

  • 1. Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients.
    Kittl EM; Ruckser R; Selleny S; Samek V; Hofmann J; Huber K; Reiner A; Ogris E; Hinterberger W; Bauer K
    Exp Clin Immunogenet; 1997; 14(4):264-72. PubMed ID: 9523162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
    Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
    Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Fanucchi A; Prontera C; Bianchi R; Genazzani AR
    Anticancer Res; 1998; 18(1B):537-9. PubMed ID: 9568174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
    Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
    Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer.
    Huang CS; Shen CY; Wang HW; Wu PE; Cheng CW
    Clin Chim Acta; 2007 Sep; 384(1-2):69-74. PubMed ID: 17651715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum big endothelin-1 levels in female patients with breast cancer.
    Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
    Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
    Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
    J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splice variant expression of CD44 in patients with breast and ovarian cancer.
    Sanchez Lockhart M; Hajos SE; Basilio FM; Mongini C; Alvarez E
    Oncol Rep; 2001; 8(1):145-51. PubMed ID: 11115587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective evaluation of CA15-3 in stage I carcinoma of the breast.
    O'Hanlon DM; Kerin MJ; Kent PJ; Skehill R; Maher D; Grimes H; Given HF
    J Am Coll Surg; 1995 Feb; 180(2):210-2. PubMed ID: 7850057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.